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Abstract 6 
Objectives: The aim of this study was to examine the influence of octopamine supplementation on 7 
endurance performance and exercise metabolism.  8 
Design: Double-blind cross-over study. 9 
Methods: Ten healthy, recreationally active men (Mean ± SD; age: 24 ± 2 y; body mass: 78.4 ± 8.7 kg; 10 
VO2peak: 50.5 ± 6.8 mL·kg−1·min−1) completed one VO2peak test, one familiarisation trial and two 11 
experimental trials. After an overnight fast, participants ingested either a placebo or 150 mg of 12 
octopamine 60 min prior to exercise. Trials consisted of 30 min of cycle exercise at 55% peak power 13 
output, followed by a 30 min performance task whereby participants completed as much work (kJ) as 14 
possible.  15 
Results: Performance was similar between the experimental trials (placebo: 352.8 ± 39.0 kJ; 16 
octopamine: 350.9 ± 38.3 kJ; Cohen’s d effect size=0.05; p=0.380). Substrate oxidation and 17 
circulating concentrations of free fatty acids, prolactin and cortisol were similar between trial 18 
conditions (all p>0.05). There were also no differences across trials for heart rate or perceived 19 
exertion during exercise (both p>0.05).  20 
Conclusions: Acute supplementation with a low dose of octopamine did not influence endurance 21 
cycle performance, substrate oxidation or circulating hormonal concentrations, which could be due to 22 
the low serum octopamine concentrations observed. Future studies should investigate the influence of 23 
larger doses of octopamine in recreationally active and well-trained individuals during prolonged 24 
exercise in temperate and high ambient conditions.  25 
 26 
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Introduction 30 
Octopamine is a naturally occurring amine structurally similar to the neurotransmitter noradrenaline.1 31 
It was first isolated from the salivary glands of the octopus2 and is synthesised from the amino acid 32 
tyrosine with tyramine as an intermediate.3 The function of octopamine is well-characterised in 33 
invertebrates, where it modulates signal transduction processes through the activation of octopamine 34 
receptors.1 Vertebrates, including humans, are absent of these receptors, which led to the suggestion 35 
that endogenous octopamine exerts no major role in human physiology.1 However, low circulating 36 
concentrations are observed in plasma,4 leading octopamine to being classified as one of the primary 37 
trace amines.5 A unique group of G protein-coupled receptors known as trace amine-associated 38 
receptors (TAAR) have been identified in recent years.6 Importantly, octopamine can bind to the 39 
TAAR1 subtype,6 a receptor which modulates the release of monoamines from presynaptic terminals 40 
in the brain.7 This confirms previous reports of the presence of octopamine in mammalian nerve 41 
tissues and brain.8 Furthermore, octopamine is suggested to play a role in the pathogenesis of 42 
Parkinson’s disease.4 Therefore, octopamine may, in part, modulate normal and abnormal 43 
neurophysiological processes5 and possess stimulant-like properties capable of influencing exercise 44 
performance.9  45 
Octopamine was studied as a therapeutic agent to treat hypotensive disorders, with doses of 450-600 46 
mg·day−1 resulting in mild increases in blood pressure without the presence of adverse effects.10 47 
Subsequent studies demonstrated the ability of octopamine to activate β3 adrenoreceptors and 48 
stimulate lipolysis,11 suggesting octopamine could influence fat metabolism. Furthermore, 49 
intracerebroventricular administration of octopamine increased locomotor activity in rats.12 Despite 50 
these observations, no human study has examined the influence of octopamine on exercise 51 
performance or substrate metabolism. Therefore, the aim of this investigation was to determine 52 
whether a low dose of octopamine could influence endurance performance and/or exercise 53 
metabolism in a group of healthy volunteers.  54 
 55 
4 
 
Methods  56 
Ten healthy, recreationally active men (age: 24 ± 2 y; body mass: 78.4 ± 8.7 kg; height: 1.81 ± 0.07 m; 57 
VO2peak: 50.5 ± 6.8 mL·kg−1·min−1; peak power output: 295 ± 41 W) participated in this study, which 58 
employed a double-blind, randomised, cross-over design. Before the study, all participants received 59 
written and verbal information regarding the nature of the investigation. Following an opportunity to 60 
ask questions, a written statement of consent was signed. All participants were free from chronic 61 
disease and deemed eligible to take part following the completion of a health screen questionnaire. 62 
The experimental protocol was approved by the Ethics Approvals (Human Participants) Sub-63 
Committee of Loughborough University, UK (Ref: R15-P072). 64 
All participants completed one incremental maximal exercise test, one familiarisation trial and two 65 
experimental trials. The initial visit consisted of incremental cycle exercise to volitional exhaustion on 66 
an electronically braked cycle ergometer (Lode Corival, Groningen, Holland) to determine peak 67 
power output at VO2peak (Wmax) and the power output required to elicit 55% and 75% of Wmax. 68 
Following this, participants completed a familiarisation trial. This was undertaken to ensure all 69 
participants were accustomed to the procedures employed during the investigation and to minimise 70 
any learning or anxiety effects. This visit was identical to the experimental trials in all respects, with 71 
the exception of no treatment being administered. All visits to the laboratory were separated by 5-7 d 72 
and were performed at the same time of day to minimise circadian-type variance. Participants were 73 
instructed to record their dietary habits and physical activity patterns during the 24 hr before the 74 
familiarisation trial and to replicate this in the 24 hr preceding the subsequent experimental trials. 75 
Additionally, no strenuous exercise, alcohol ingestion or excessive caffeine consumption (i.e. above 76 
habitual intake) was permitted during the 24 hr before each experimental trial. Compliance to these 77 
measures was verified upon arrival at the laboratory, prior to any data collection.  78 
Participants arrived at the laboratory in the morning (7-9 am) following an overnight fast (8-12 hr) 79 
with the exception of ingesting 500 mL of plain water approximately 90 min before arrival. Post-void 80 
nude body mass was recorded upon arrival (Adam AFW-120K, Milton Keynes, UK) and a heart rate 81 
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telemetry band (Polar Beat, Kempele, Finland) was positioned. Participants then rested in a seated 82 
position for 15 min before a 21-g cannula was inserted into an antecubital vein to enable repeated 83 
blood sampling; this was flushed with a small volume of saline after each sample to ensure patency. A 84 
baseline venous sample (12 mL) was collected before participants ingested a capsule containing either 85 
150 mg of starch (placebo) or 150 mg of octopamine (Blackburn Distributions, Lancashire, UK) with 86 
a small volume of water (50 mL). The purity of octopamine was certified at >99% (HFL Sport 87 
Science, Fordham, UK; Ref: LGC255966). The 150 mg dose was chosen to avoid hypertensive effects 88 
reported after oral intakes of 450-600 mg in hypotensive patients.10 All capsules were visually 89 
identical and blinded by an external party not involved in any stage of data collection. Following 90 
ingestion of the capsules, participants rested in a comfortable environment for 60 min; this timeframe 91 
is sufficient to elicit peak octopamine concentrations in the blood.13 After the rest period, a second 92 
venous sample (12 mL) was collected before participants began cycle exercise for 30 min at a 93 
workload corresponding to 55% Wmax. During this period heart rate and rating of perceived exertion 94 
(RPE) were recorded every 5 and 10 min, respectively.14 Expired gas samples (1 min) were collected 95 
into Douglas bags at 15 and 30 min to determine the rates of fat and carbohydrate oxidation.15 Oxygen 96 
and carbon dioxide concentrations in each bag were determined with a paramagnetic analyser 97 
(Servomex 1400, Sussex, UK) calibrated against gases of known concentration on the morning of 98 
each trial. Total volume was quantified (Harvard Dry Gas Meter, Harvard Apparatus, USA) and gas 99 
values were expressed as STPD. Following the collection of each sample, participants were provided 100 
with 100 mL of plain water. After the 30 min, a third venous sample (12 mL) was collected while 101 
participants remained seated on the ergometer.  102 
Subsequently, there was a 2-3 min delay while the ergometer was set up for the performance task. 103 
Participants were instructed to complete as much work (kJ) as possible within 30 min. This method of 104 
measuring performance is consistent with previous studies which examined the performance benefits 105 
of stimulants such as caffeine.16,17 Furthermore, this performance test elicits a coefficient of variation 106 
of approximately 3% in recreationally active participants following one familiarisation trial,18 107 
indicating a similar test-retest reliability to the energy-based time-trial protocols.19 Participants began 108 
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exercise at a workload corresponding to 75% Wmax, but were free to adjust their workload as desired 109 
from the outset. During this period participants received feedback regarding time elapsed and cadence, 110 
but no other information or verbal encouragement was provided and contact was limited to the 111 
recording of the physiological and perceptual variables. Heart rate was recorded every 5 min and RPE 112 
at 10 and 20 min, respectively. A final venous sample (12 mL) was collected upon completion of 113 
exercise while participants remained seated on the ergometer. After this, the cannula was removed.  114 
All venous samples were drawn directly into dry syringes. A small volume (2 mL) was dispensed into 115 
tubes containing K2EDTA. Duplicate 100 μL aliquots were rapidly deproteinised in 1 mL of ice-cold 116 
0.3N perchloric acid. These were centrifuged and the resulting supernatant used to determine blood 117 
glucose concentrations (GOD-PAP, Randox Ltd, UK). Haemoglobin (cyanmethemoglobin method) 118 
and haematocrit (microcentrifugation) values were used to estimate percentage changes in blood and 119 
plasma volumes relative to the resting sample.20 A separate 5 mL was dispensed into tubes containing 120 
K2EDTA and a further 5 mL was dispensed into tubes containing clotting activator; both aliquots 121 
were left on ice for 60 min prior to centrifugation at 1750 g for 10 min at 4°C. The resulting plasma 122 
from the K2EDTA treated blood was stored at -21°C for the subsequent determination of free fatty 123 
acids (FFA; Randox laboratories Ltd, Crumlin, UK) by colorimetric methods. The resulting serum 124 
from the clotted blood was stored at -21°C for the subsequent determination of prolactin and cortisol 125 
with ELISA (DRG diagnostics, Germany) and octopamine with a modified reverse-phase HPLC 126 
method as previously described.21  127 
All data were analysed using IBM SPSS statistics version 21.0. Normality was assessed with the 128 
Shapiro Wilk test. To evaluate differences in exercise performance, pre-exercise nude body mass, and 129 
fasting plasma glucose across trial conditions, a paired t-test was employed. Cohen’s d effect size (ES) 130 
for differences in total work produced during the performance task was determined ([mean 1 - mean 131 
2]/pooled SD) and interpreted as trivial (0-0.19), small (0.2-0.49), medium (0.5-0.79) or large (>0.8) 132 
as previously described.22 Variables measured throughout each trial were analysed using a two-way 133 
(trial x time) repeated-measures ANOVA. Where the assumption of sphericity had been violated, the 134 
degrees of freedom were corrected with a Greenhouse-Geisser as appropriate. Main effects and 135 
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interactions were followed up with Bonferroni adjusted paired t-tests for normally distributed data or 136 
Bonferroni adjusted Wilcoxon Signed Rank tests for non-normally distributed data. Data are 137 
presented as means ± SD throughout. Statistical significance was accepted at p<0.05. 138 
 139 
Results 140 
Mean environmental temperature was similar between trials (placebo: 20.0 ± 0.8°C; octopamine: 20.0 141 
± 0.8°C; p=0.903). There were no differences across trials for pre-exercise nude body mass (placebo: 142 
78.6 ± 8.8 kg; octopamine: 78.7 ± 8.9 kg; p=0.602) or fasting plasma glucose (placebo: 4.4 ± 0.5 143 
mmol∙L-1; octopamine: 4.4 ± 0.5 mmol∙L-1; p=0.483), suggesting that participants began each trial in a 144 
similar physiological state.  145 
All ten participants completed both experimental trials, no adverse effects were reported. There was 146 
no clear difference in total work produced during the performance task, with mean values of 352.8 ± 147 
39.0 kJ and 350.9 ± 38.3 kJ recorded during the placebo and octopamine trials, respectively (ES=0.05; 148 
p=0.380; Figure. 1a).  149 
Serum octopamine concentrations remained below the limit of detection for all time points during the 150 
placebo trial and for the baseline sample during the octopamine trial. During the octopamine trial 151 
serum concentrations increased (p<0.05), with mean values of 0.95 ± 0.50, 1.11 ± 0.25 and 1.24 ± 152 
0.18 μM recorded at 60, 90 and 120 min post-capsule ingestion, respectively. No pair-wise differences 153 
were identified from 60 to 120 min post-ingestion (p>0.725).  154 
Circulating cortisol showed a main effect of time (p<0.05), but no main effect of trial (p=0.334) or a 155 
trial x time interaction (p=0.080; Figure 2a). There was a main effect of time for serum prolactin 156 
(p<0.05), with higher values recorded at 30 and 60 min compared with baseline (p<0.05; Figure 2b). 157 
No main effect of trial (p=0.833) or interaction effect (p=0.288) was observed. FFA concentrations 158 
remained similar compared with baseline during both trials, with no main effect of time (p=0.783), 159 
trial (p=0.351) or trial x time interaction (p=0.412; Figure 2c). Glucose concentrations showed a main 160 
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effect of time (p<0.05), with higher values at 30 and 60 min compared with baseline (p<0.05; Figure 161 
2d). No main effect of trial (p=0.240) or interaction effect (p=0.704) was apparent. There were main 162 
effects of time for blood and plasma volume (p<0.05), but no main effects of trial (p>0.231) or trial x 163 
time interactions (p>0.504). 164 
There was a main effect of time for fat oxidation (p=0.026), but no main effect of trial (p=0.597) or 165 
interaction effect (p=0.387; Table. 1). For carbohydrate oxidation there was no main effect of trial 166 
(p=0.661), time (p=0.148) or a trial x time interaction (p=0.419). Oxygen uptake showed a main effect 167 
of time (p=0.001), with higher values at 30 min compared with 15 min (p<0.05; Table. 1). No main 168 
effect of trial (p=0.927) or interaction effect (p=0.382) was observed. For RER there was no main 169 
effect of trial (p=0.775), time (p=0.121) or a trial x time interaction (p=0.366; Table 1).  170 
Heart rate showed a main effect of time during the fixed-intensity exercise (p<0.05), with similar 171 
mean values across trials (placebo: 136 ± 5 bpm; octopamine: 135 ± 5 bpm; p=0.240). No trial x time 172 
interaction was observed (p=0.893). Heart rate showed a main effect of time during the performance 173 
task (p<0.05). Mean values were similar between trials (placebo: 168 ± 7 bpm; octopamine: 168 ± 6 174 
bpm; p=0.625) and no interaction effect occurred (p=0.168).  175 
There was a main effect of time for RPE during the fixed-intensity exercise (p=0.010). Mean values 176 
were similar between trial conditions (placebo: 12.6 ± 0.4; octopamine: 12.3 ± 0.5; p=0.343) and no 177 
trial x time interaction was observed (p=0.241). Similarly, there was a main effect of time for RPE 178 
during the performance task (p<0.05). Mean values were similar between trials (placebo: 16.7 ± 0.6; 179 
octopamine: 16.5 ± 0.5; p=0.177) and no interaction effect occurred (p=0.798).  180 
 181 
Discussion:  182 
The present study was the first to examine whether a low dose of octopamine could influence 183 
endurance cycling performance or exercise metabolism in a group of healthy, recreationally active 184 
male participants. The present findings demonstrate that an acute 150 mg dose did not enhance 185 
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performance versus placebo, with a mean difference between trials of 1.9 ± 6.6 kJ (0.5 ± 1.9%; Figure 186 
1a). While one participant produced 15.5 kJ (4.6%) less work during the octopamine trial compared 187 
with placebo, the individual changes in performance by the remaining participants were consistent 188 
and small (<3%; Figure 1b). Therefore, it seems likely that any variation in performance is 189 
attributable to day-to-day variability in the performance test.18 Furthermore, substrate oxidation rates 190 
and the circulating concentrations of FFA’s, prolactin and cortisol were similar between trials.  191 
While the mechanism of action of octopamine is well-established in invertebrates,1 its precise 192 
function in humans remains elusive.5 However, low concentrations have been observed in plasma4 193 
and throughout the central nervous system.5,7,8 Previous work demonstrated that octopamine binds to 194 
TAAR1,6 a receptor which modulates neurotransmitter release across several brain regions.7 However, 195 
the EC50 values for TAAR1 from human, rat and mouse transfected-cell lines are in the range of 2-20 196 
μM.23 These values are greater than the serum concentrations reported in the present study (0.95 to 197 
1.24 μM), suggesting a larger dose of octopamine may be required to influence this receptor. 198 
Furthermore, octopamine is rapidly metabolised after oral ingestion, with approximately eleven times 199 
more conjugated octopamine present in the urine compared with intravenous infusion.13 This might 200 
explain the contrast between the present study and a previous animal model,12 as octopamine was 201 
directly introduced into the brain of rats and therefore not subjected to extensive hepatic first-pass 202 
metabolism. Furthermore, endurance performance in the heat is influenced by pharmacological 203 
manipulation of central catecholamines.24 Hence, the provision of a larger dose of octopamine 204 
coupled with a high ambient temperature could provide conditions by which octopamine might 205 
enhance performance; this hypothesis warrants investigation in future studies.  206 
Previous research demonstrated that octopamine can selectively and potently bind to β3 207 
adrenoreceptors and stimulate lipolysis in mammalian fat cells,11 suggesting oral supplementation 208 
might influence fat metabolism in humans. However, no differences were observed between the two 209 
trials in the estimated rates of fat and carbohydrate oxidation or the peripheral concentrations of FFA. 210 
While these findings contrast with previous in vitro data,11 the doses required to induce lipolysis in 211 
these experiments ranges from 10 μM to 1 mM.11,25 Therefore, observations from in vitro models may 212 
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not reflect the physiological responses observed after oral intake in humans. Furthermore, even 213 
chronic ingestion (4 wk) of a dose approximately seven times greater than the present study (15.3 214 
mg·kg−1) failed to induce higher FFA, glycerol or triglyceride concentrations in rats.26 For an 80 kg 215 
human, this corresponds to a daily dose of approximately 1,200 mg, which is twice the dose 216 
demonstrated to induce hypertensive effects.10 Hence, it is unlikely that acute low doses of 217 
octopamine (~150 mg) influence fat metabolism in humans.  218 
 219 
Conclusion 220 
Under the conditions of the present study, octopamine supplementation did not influence endurance 221 
performance, substrate oxidation or the peripheral concentrations of FFA’s, cortisol and prolactin. 222 
These findings may be due to the low serum concentrations observed. As such, future studies should 223 
examine the performance and metabolic responses to larger intakes of octopamine (300-400 mg). 224 
Furthermore, given the training status of the participants in the present investigation (recreationally 225 
active), it would be of interest to investigate the effects of octopamine in well-trained individuals. As 226 
central catecholaminergic neurotransmission can modulate endurance performance in the heat,24 the 227 
influence of a high ambient temperature on the ergogenic potential of octopamine should also be 228 
investigated. Nevertheless, the results of the present study may be of interest to the World Anti-229 
Doping Agency, given octopamine is currently on the list of prohibited substances, meaning its use is 230 
banned in competition.9  231 
 232 
Practical applications 233 
• An acute 150 mg dose of octopamine may not enhance endurance performance in temperate 234 
conditions.   235 
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• At the dose prescribed in the present study, octopamine does not appreciably influence 236 
markers of fat metabolism, hormonal concentrations, heart rate or perceived exertion during 237 
exercise.  238 
• Given the lack of research, individuals should refrain from consuming octopamine until more 239 
studies have investigated whether this stimulant can influence endurance performance or 240 
metabolism. 241 
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Table 1: Substrate oxidation and oxygen uptake during the fixed-intensity exercise 314 
CHO ox, carbohydrate oxidation; Fat ox, fat oxidation; RER, respiratory exchange ratio; VO2, Oxygen uptake. *Significant difference (P<0.05) compared with the 15 min 315 
value. 316 
 317 
 318 
 Placebo Octopamine 
 15 30 15 30 
CHO ox (g·min−1) 
Fat ox (g·min−1) 
RER 
VO2 (L·min−1) 
2.46 ± 0.35 
0.19 ± 0.08 
0.95 ± 0.02 
2.22 ± 0.30 
2.46 ± 0.37 
0.23 ± 0.08 
0.94 ± 0.02 
2.29 ± 0.31* 
2.44 ± 0.38 
0.20 ± 0.04 
0.94 ± 0.01 
2.21 ± 0.31 
2.51 ± 0.33 
0.21 ± 0.05 
0.94 ± 0.01 
2.29 ± 0.30* 
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Figure Captions 319 
Figure 1: Total work produced (a) and individual responses (b) during the experimental trials. 320 
Figure 2: Circulating concentrations of cortisol (a), prolactin (b), free fatty acids (c) and 321 
glucose (d) during the experimental trials. *denotes a significant difference (P<0.05) 322 
compared with the -60 value.  323 
 324 
 325 
 326 
 327 
 328 
 329 
 330 
 331 
 332 
 333 
 334 
 335 
 336 
 337 
17 
 
Figure 1 338 
 339 
 340 
 341 
 342 
 343 
 344 
 345 
 346 
300
310
320
330
340
350
360
370
380
390
400
Placebo Octopamine
W
or
k 
pr
od
cu
ed
 (k
J) 
a 
280
300
320
340
360
380
400
420
440
Placebo Octopamine
W
or
k 
pr
od
uc
ed
 (k
J) 
b 
18 
 
Figure 2 347 
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